Abstract:Objective To investigate the clinical features of the pre-formed and de novo human leucocyte antigen (HLA) antibodies post-kidney transplantation,and the clues to clinical strategy.Methods The Luminex assays were used to detect the HLA antibodies in the pre-and post-operative serum samples of the kidney transplant recipients.The variation trends of the pre-formed and de novo HLA antibodies post-transplantation were analyzed based on the HLA antibody assessment,gene typing and clinical data.The potential factors that may affect the outcome,persistent or not,of the de novo anti-donor specific HLA antibody (DSA) were also determined.Finally,the effect of the HLA mismatch on the risk of the development of the de novo DSA was investigated.Results Pre-formed HLA antibodies were detected in 9 recipients (8.0％,9/113),of which 88.9％ (8/9) developed HLA-Ⅰ antibodies,including one with DSA.All of the pre-formed antibodies were cleared in 6 (1-36) months post-transplant.The serum creatinine (SCr) of these recipients in 1,6,12,36,60 months were 125.0 (82-591),102.0 (84-105),98.0 (76-131),111.5 (75-137) and 89.0 (68-125) mmol/L,respectively.20 recipients (19.2％,20/104) developed de novo HLA antibodies,of which 6 were with transient HLA antibodies (Class Ⅰ,n=3;Class Ⅱ,n=3) and 14 were persistent (Class Ⅰ,n=2;Class Ⅱ,n=10;Class Ⅰ + Ⅱ,n =2).One of the six recipients with transient antibodies developed DSA,while 12/14 recipients with persistent antibodies had DSA (P =0.003).The cumulative rate of the recipients with HLA DSA in 1,2 and 3-6 years were around 1/3,respectively.Totally 25 DSA were detected in 13 de novo HLA DSA positive recipients.The majority of the DSA was HLA-Ⅱ (80.0％,20/25),and most of them were DQ DSA (80.0％,16/20).The initial and the peak titers were higher in the persistent DSA versus that in transient DSA (P =0.059,P =0.027),presenting an increasing manner (P =0.017).Comparing to HLA-Ⅰ,HLA-Ⅱ DSA were more likely to be persistent (P =0.016).However,there was no difference in the first-time-appearance between persistent and transient DSA (P =0.501).Comparing to HLA-A,B,C and DR loci,HLA-DQ mismatch showed a higher risk of developing DSA (P =0.019,0.000,0.000 and 0.015,respectively),which was observed in a dose-dependent manner (P =0.084).Conclusion With an intensive two-year post-transplant follow-up,the recipient candidates with low to moderate pre-formed HLA NDSA can be acceptable for the kidney transplantation.Class Ⅱ,high titer,especially with an increasing trend were risk factors for the persistence of the de novo HLA DSA.DQ matching is an important way to prevent the development of the de novo HLA DSA.

HLA antigen and HLA eplet mismatches - important factors for developing donor-specific antibodies after kidney transplantation

Impact of HLA Eplet Mismatch on De Novo Donor Specific Antibody Formation After Kidney Transplantation

Class II Human Leukocyte Antigen Epitope Mismatch Predicts De Novo Donor‐Specific Antibody Formation After Liver Transplantation

Impact of Alloantibody Strength in Crossmatch Negative DSA Positive Kidney Transplantation

Association of HLA B‐ and T‐cell molecular mismatches with HLA antibodies, rejection, and graft survival in pediatric kidney transplantation

Repeated human leukocyte antigens eplets, importance of typing the partner

HLA Amino Acid Polymorphisms and Kidney Allograft Survival

High-Risk HLA-DQ Mismatches Are Associated With Adverse Outcomes After Lung Transplantation

HLA, Non-HLA Antibodies, and Eplet Mismatches in Pediatric Liver Transplantation: Observations from a Small, Single-Center Cohort.

HLA-DR/DQ eplet mismatch predicts de novo donor-specific antibody development in multi-ethnic Southeast Asian kidney transplant recipients on different immunosuppression regimens

HLA B Eplet Mismatches in the Context of Delayed Graft Function and Low Tacrolimus Trough Levels Are Risk Factors Influencing the Generation of De Novo Donor-Specific Antibodies and Acute Rejection in the Early Stage after Kidney Transplantation.

The clinical features of the pre-formed and de novo human leucocyte antigen antibodies post-kidney transplantation: a single center analysis of the eight-year follow-up data

Allogeneic HLA Humoral Immunogenicity and the Prediction of Donor-Specific HLA Antibody Development

Determination of the clinical relevance of donor epitope‐specific HLA‐antibodies in kidney transplantation

Using Machine Learning to Examine Pre-Transplant Factors Influencing De novo HLA-Specific Antibody Development Post-Kidney Transplant

The Impact of HLA-DQαβ Heterodimer Mismatch on Living Donor Kidney Allograft Outcomes

HLA molecular mismatches and induced donor-specific tolerance in combined living donor kidney and hematopoietic stem cell transplantation

Development of Nondonor-Specific Hla-Dr Antibodies in Allograft Recipients is Associated with Shared Epitopes with Mismatched Donor Dr Antigens

Dissecting the impact of molecular T-cell HLA mismatches in kidney transplant failure: A retrospective cohort study

Clinical relevance of HLA-DQ eplet mismatch and maintenance immunosuppression with risk of allosensitization after kidney transplant failure

Predicting the risk of dn DSA-mediated acute rejection based upon Eplet and EMS matching